Long-term complete remission of metastatic adrenocortical carcinoma

Jersy Cárdenas-Salas; Beatriz Castelo; Rita María Regojo; Juan Antonio González-Sanchez; Cristina Álvarez-Escolá

doi:10.1515/hmbci-2022-0017

Article

Long-term complete remission of metastatic adrenocortical carcinoma

Jersy Cárdenas-Salas , Beatriz Castelo , Rita María Regojo , Juan Antonio González-Sanchez and Cristina Álvarez-Escolá

Published/Copyright: September 8, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Hormone Molecular Biology and Clinical Investigation Volume 44 Issue 1

Abstract

Objectives

To report a rare case of a metastatic adrenocortical carcinoma (ACC) that achieve a complete and a long-term remission.

Case presentation

AAC is a rare and aggressive tumor, with a high risk of recurrence and that present metastases in 21% of cases at diagnosis. Treatment of advanced ACC is challenging, mitotane is the only available adrenolytic treatment, with modest and unpredictable responses. Response rates to systemic chemotherapy are not encouraging. We describe the case of a 39-year-old woman with a metastatic ACC, that achieve a complete and long-term remission after chemotherapy, mitotane treatment and surgery of primary tumor and liver metastases.

Conclusions

A complete remission of a metastatic adrenocortical carcinoma is possible in some rare cases after a multimodal treatment.

Keywords: adrenocortical carcinoma; metastatic; remission

Corresponding author: Cristina Álvarez-Escolá, Department of Endocrinology, “La Paz” University Hospital, Paseo de la Castellana, 261, 28046, Madrid, Spain, Phone: +34-917277209, E-mail: escola.cristina@gmail.com

Research funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Author contributions: CAA & JJCS were the main writers of the manuscript. CAA is the named physician of the patient. All the team members reviewed the manuscript and helped in the patient care, diagnosis and follow-up. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Ethical approval: Not applicable. Approval by an ethics committee was not obtained nor sought after due to the current manuscript representing a single-patient case report, describing what is known to be standard of care involving minimal risk.

References

1. Fassnacht, M, Kroiss, M, Allolio, B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013;98:4551–64. https://doi.org/10.1210/jc.2013-3020.Search in Google Scholar PubMed

2. Fassnacht, M, Johanssen, S, Quinkler, M, Bucsky, P, Willenberg, HS, Beuschlein, F, et al.. German adrenocortical carcinoma registry group, & European network for the study of adrenal tumors. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009;115:243–50. https://doi.org/10.1002/cncr.24030.Search in Google Scholar PubMed

3. Baudin, E, Pellegriti, G, Bonnay, M, Penfornis, A, Laplanche, A, Vassal, G, et al.. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385–92.10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2Search in Google Scholar

4. Puglisi, S, Calabrese, A, Basile, V, Pia, A, Reimondo, G, Perotti, P, et al.. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metabol 2020;34:101415. https://doi.org/10.1016/j.beem.2020.101415.Search in Google Scholar

5. Fassnacht, M, Terzolo, M, Allolio, B, Baudin, E, Haak, H, Berruti, A, et al.. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189–97. https://doi.org/10.1056/NEJMoa1200966.Search in Google Scholar

6. Datrice, NM, Langan, RC, Ripley, RT, Kemp, CD, Stinberg, SM, Wood, BJ, et al.. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012;105:709–13. https://doi.org/10.1002/jso.23015.Search in Google Scholar

7. Else, T, Kim, AC, Sabolch, A, Raymond, VM, Kandathil, A, Caoili, EM, et al.. Adrenocortical carcinoma. Endocr Rev 2014;35:282–326. https://doi.org/10.1210/er.2013-1029.Search in Google Scholar

8. Berruti, A, Grisanti, S, Pulzer, A, Claps, M, Daffara, F, Loli, P, et al.. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab 2017;102:1358–65. https://doi.org/10.1210/jc.2016-2894.Search in Google Scholar

9. Abiven, G, Coste, J, Groussin, L, Anract, P, Tissier, F, Legmann, P, et al.. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650–5. https://doi.org/10.1210/jc.2005-2730.Search in Google Scholar

10. Becker, D, Schumacher, OP. o,p’DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975;82:677–9. https://doi.org/10.7326/0003-4819-82-5-677.Search in Google Scholar

11. Kornely, E, Schlaghecke, R. Complete remission of metastasized adrenocortical carcinoma under o,p’-DDD. Exp Clin Endocrinol 1994;102:50–3. https://doi.org/10.1055/s-0029-1211265.Search in Google Scholar PubMed

12. Sakamoto, K, Ariyoshi, A, Okazaki, M. Metastatic adrenocortical carcinoma treated by repeated resection: a case report of long-term survival over 18 years. Int J Urol 1995;2:50–2.10.1111/j.1442-2042.1995.tb00621.xSearch in Google Scholar

13. Godil, MA, Atlas, MP, Parker, RI, Priebe, CJ, Zerah, MM, Kane, P, et al.. Metastatic congenital adrenocortical carcinoma: a case report with tumor remission at 3 1/2 years. J Clin Endocrinol Metab 2000;85:3964–7. https://doi.org/10.1210/jcem.85.11.6939.Search in Google Scholar PubMed

14. Ilias, I, Alevizaki, M, Philippou, G, Anastasiou, E, Souvatzoglou, A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 2001;24:532–5. https://doi.org/10.1007/BF03343888.Search in Google Scholar PubMed

15. De León, DD, Lange, BJ, Walterhouse, D, Moshang, T. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2002;87:4452–6. https://doi.org/10.1210/jc.2001-011978.Search in Google Scholar PubMed

16. Plaza, CPR, Santoyo, JS, López, MED, Carrasco, CEG, Dols, MC, Muñoz, MAS, et al.. [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy]. Arch Esp Urol 2005;58:115–9. https://doi.org/10.4321/s0004-06142005000200004.Search in Google Scholar PubMed

17. Arai, H, Rino, Y, Yamanaka, S, Yukawa, N, Wada, N, Kato, H, et al.. Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case. Surg Today 2008;38:965–9. https://doi.org/10.1007/s00595-008-3788-5.Search in Google Scholar PubMed

18. Chalasani, S, Vats, HS, Banerjee, TK, McKenzie, AK. Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. Clin Med Res 2009;7:48–51. https://doi.org/10.3121/cmr.2009.821.Search in Google Scholar PubMed PubMed Central

19. Pal, SK, Gartrell, B, Olsson, CA, Stein, CA. Metastatic adrenocortical carcinoma with a prolonged response to mitotane. Oncology 2014;28:624–625, 642.Search in Google Scholar

Received: 2022-02-06

Accepted: 2022-07-20

Published Online: 2022-09-08

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/hmbci-2022-0017

Keywords for this article

adrenocortical carcinoma; metastatic; remission